Sionna Therapeutics (SION) Stock Price, News & Analysis

Company Overview

Sionna Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing precision medicines for inflammatory and vascular diseases. The company leverages a proprietary targeted protein degradation platform designed to selectively eliminate disease-driving proteins in the endothelium. By engineering modular molecules that bind and shuttle pathological targets to the cellular degradation machinery, Sionna seeks to address mechanisms underlying conditions such as pulmonary arterial hypertension and diabetic nephropathy.

The company’s pipeline comprises several preclinical and early-stage clinical programs aimed at modulating key inflammatory pathways and restoring vascular homeostasis. Lead candidates are designed to penetrate tissue barriers and induce sustained clearance of overactive proteins, offering a differentiated approach versus traditional small-molecule inhibitors or biologics. Sionna maintains active research collaborations with academic institutions and contract research organizations to optimize its delivery technologies and expand its therapeutic reach.

Founded in 2020, Sionna Therapeutics is headquartered in Cambridge, Massachusetts, with additional research operations in North America and Europe. The executive team brings together experienced professionals from the biopharmaceutical industry, combining expertise in protein engineering, drug development and clinical operations. Sionna’s leadership has emphasized rapid advancement of its most promising candidates through clinical proof-of-concept studies while continuing to broaden its platform capabilities for future indications.

Key Stats

• Today's Range: $16.46 to $17.45
• 50-Day Range: $12.00 to $21.57
• 52-Week Range: $7.26 to $25.19
• Volume: 102,397 shs
• Average Volume: 276,979 shs
• Market Capitalization: $769.45 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $38.50
• Consensus Rating: Buy

SION Stock Analysis - Frequently Asked Questions

How have SION shares performed this year?

Sionna Therapeutics' stock was trading at $20.10 on January 1st, 2025. Since then, SION stock has decreased by 13.2% and is now trading at $17.44.

How were Sionna Therapeutics' earnings last quarter?

Sionna Therapeutics, Inc. (NASDAQ:SION) posted its quarterly earnings results on Monday, May, 12th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.45) by $0.17.

When did Sionna Therapeutics IPO?

Sionna Therapeutics (SION) raised $191 million in an initial public offering (IPO) on Friday, February 7th 2025. The company issued 10,588,233 shares at a price of $18.00 per share.

When does the company's lock-up period expire?

Sionna Therapeutics's lock-up period expires on Wednesday, August 6th. Sionna Therapeutics had issued 10,588,233 shares in its public offering on February 7th. The total size of the offering was $190,588,194 based on an initial share price of $18.00. After the end of the company's lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company will be lifted.

How do I buy shares of Sionna Therapeutics?

Shares of SION stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 5/12/2025
• Today: 7/21/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SION
• Previous Symbol: NASDAQ:SION
• CIK: 2036042
• Web: N/A
• Phone: (617) 819-2020
• Fax: N/A
• Employees: 35
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Sionna Therapeutics: $38.50
• High Price Target: $45.00
• Low Price Target: $32.00
• Potential Upside/Downside: +120.8%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 28.73
• Quick Ratio: 28.73

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 44,120,000
• Free Float: 42,403,000
• Market Cap: $769.45 million
• Optionable: N/A
• Beta: N/A